# **Munich Cancer Registry**



- ▶ Survival
- ▶ Selection Matrix
- ▶ Homepage
- ▶ Deutsch

Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

# **Cancer statistics: Baseline statistics**

# C05.1, C05.2, C09-C14: Pharynx cancer

Year of diagnosis	1998-2013
Patients	3,507
Diseases	3,564
Creation date	05/19/2015
Export date	12/30/2014
Population	4.64 m



http://www.tumorregister-muenchen.de/en/facts/base/base\_C0914E.pdf

# Global Statements about the statistics on the Internet – Baseline Statistics (grey button ——), Survival (red button ——)

In these analyses, the clinics and physicians of Upper Bavaria and the city and county of Landshut<sup>#</sup>, with a total of 4.64 million inhabitants, account for the frequency of cancer diseases<sup>##</sup> and the achieved long term results. Additionally, the long term survival evaluated by the Munich Cancer Registry (MCR) is compared with the results of the population-based registry in the USA (SEER), which is useful for checking the consistency of the data on an international level.

In comparing several tables, inconsistent figures may be detected. This is based on the fact that different patient cohorts are included in the base calculation, for example when proportions of multiple tumors or DCO-cases\*\*\*\* are concerned. In other cases the individual tumor diagnosis is the basis for calculation, for example with incidence.

The foot notes describe the currentness of the data. The baseline statistics and survival data are updated annually. This yearly analysis comprises the Annual Report of the MCR. The time-delayed acquisition of data and the occasionally high DCO-rates indicate optimizing reserves, among others, because of current financial and legal conditions that hinder the analyses.

Clinics and physicians have access to essentially more detailed data, with which they can check, compare and in the best case optimize their own data and results.

We would be pleased to receive corrections, critique and useful suggestions. Just send an e-mail to tumor@ibe.med.uni-muenchen.de.

Munich Cancer Registry, May 2015

- <sup>#</sup> Base data has been collected since 1998. An increase in new diseases is apparent, which is an effect of two extensions in the MCR catchment area (from a base population of 2.51 million to 3.96 in 2002, and to 4.52 million in 2007). Death certificates from 2014 are incorporated into these analyses.
- Due to the high frequency and good prognosis of non-malignant skin cancer (C44), no systematic ascertainment is performed for this diagnosis. C44 is not designated as a primary, but rather as a secondary tumor.
- DCO (death certificate only) identifies a cancer case that first becomes available to the MCR through the death certificate. A high proportion of DCO cases (≥5%) in particular cancer types indicate insufficient participation of specific cancer specializations.

#### Some remarks regarding this cancer type

As a general rule, these few results from the TRM form the basis of sophisticated analyses. For head and neck tumors this is not the case. Therefore the results for head and neck tumors should be interpreted with caution. In part this is due to problems of classification because of limited specific details of locality. Additionally, with advanced tumors in a close topographic location it is often not possible to determine the exact ICD localization of a tumor.

## ICD-10 codes (ICD-10 2015) used for specifying cancer site

Code	Description
C05.1 C05.2	Soft palate Uvula
C09	Tonsil
C10	Oropharynx Excl.: Topography code C10.1 Anterior surface of epiglottis
C11	Nasopharynx
C12	Piriform sinus
C13	Hypopharynx
C14	Other and ill-defined sites in the lip, oral cavity and pharynx

#### **INCIDENCE**

Table 1

Patient cohorts by year of diagnosis including DCO cases and multiple primaries, and with proportion of deaths and active follow-up

				Prop.		Prop.
		DCO	Prop.	mult.	Prop.	actively
Year of	Cases	cases	DCO	primaries	deaths	followed
diagnosis	n	n	%	%	%	%
1998	145	7	4.8	26.2	84.1	100.0
1999	162	8	4.9	23.5	80.9	98.8
2000	138	5	3.6	27.5	82.6	97.1
2001	145	8	5.5	29.0	75.9	95.9
2002	228	20	8.8	31.1	77.2	98.2 #
2003	242	5	2.1	31.8	78.9	98.3
2004	212	8	3.8	27.8	75.9	98.6
2005	263	14	5.3	31.6	67.3	97.0
2006	236	5	2.1	26.7	66.9	97.5
2007	277	25	9.0	27.4	64.6	92.1 # ##
2008	301	12	4.0	30.2	66.4	82.4
2009	285	8	2.8	29.8	63.9	82.1
2010	279	13	4.7	28.3	52.3	76.7
2011	271	14	5.2	31.4	49.1	80.1
2012	258	18	7.0	23.6	42.2	80.6
2013	122	9	7.4	29.5	39.3	100.0 ###
1998-2013	3564	179	5.0	28.7	65.6	90.7

<sup>#</sup> The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

### Please be aware that data of recent annual patient cohorts may not yet be fully processed. Therefore, the presented figures and tables are potentially related to different time periods as pointed out in the respective headlines or legends.

<sup>##</sup> Since 2007 the percentage of actively followed patients sharply declined compared to the previous years. This is a consequence of ambiguous data protection rules that currently forbid cancer registries in Bavaria to obtain the essential life status informations from competent registration offices.

Table 1a

Patient cohorts by year of diagnosis and gender including DCO cases

Year of	All /	Males	Females	Prop. males
diagnosis	n /	n	n	%
1998	145	125	20	86.2
1999	162	134	28	82.7
2000	138	110	28	79.7
2001	145	121	24	83.4
2002	228	196	32	86.0
2003	242	195	47	80.6
2004	212	180	32	84.9
2005	263	211	52	80.2
2006	236	179	57	75.8
2007	277	224	53	80.9
2008	301	231	70	76.7
2009	285	226	59	79.3
2010	279	225	54	80.6
2011	271	211	60	77.9
2012	258	199	59	77.1
2013	122	90	32	73.8
1998-2013	3564	2857	707	80.2

Table 2

Incidence measures by year of diagnosis and gender including DCO cases (with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.64 m as of 2007, respectively)

			Males	Fem.	Males	Fem.	Males	Fem.	Males	Fem.
Year of	Males	Females	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.
diagnosis	n	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
1998	125	20	11.3	1.7	7.6	0.9	10.1	1.4	10.8	1.5
1999	134	28	12.0	2.4	7.9	1.3	10.9	1.8	11.9	2.1
2000	110	28	9.7	2.3	6.4	1.5	8.9	2.0	9.9	2.1
2001	121	24	10.4	2.0	7.0	1.2	9.5	1.7	10.3	1.8
2002	196	32 <	10.5	1.6	6.9	1.0	9.4	1.3	10.1	1.5
2003	195	47	10.4	2.4	6.9	1.4	9.5	1.9	10.1	2.1
2004	180	32	9.6	1.6	6.3	0.8	8.6	1.2	9.3	1.4
2005	211	52	11.1	2.6	7.2	1.5	9.7	2.1	10.5	2.4
2006	179	57	9.3	2.8	6.0	1.8	8.3	2.5	9.1	2.6
2007	224	53	10.1	2.3	6.1	1.3	8.5	1.8	9.6	2.0
2008	231	70	10.4	3.0	6.5	1.6	8.9	2.1	9.9	2.5
2009	226	59	10.1	2.5	6.2	1.4	8.5	2.0	9.5	2.2
2010	225	54	10.0	2.3	6.1	1.4	8.3	1.9	9.2	2.0
2011	211	60	9.2	2.5	5.3	1.5	7.4	2.0	8.5	2.2
2012	199	59	8.7	2.5	5.2	1.3	7.2	1.9	8.1	2.1
2013	90	32	3.9	1.4	2.4	0.8	3.3	1.1	3.7	1.1
1998-2013	2857	707	9.6	2.3	6.0	1.3	8.3	1.8	9.1	2.0




Table 3

Age distribution parameters by year of diagnosis (All) (incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	145	57.7	10,7	0.9	87.6	46.9	51.6	57.3	63.5	70.7
1999	162	59.3	11.0	32.7	91.7	48.1	51.3	57.7	65.0	75.2
2000	138	59.1	10.4	31.0	89.6	47.9	51.8	58.0	65.0	74.1
2001	145	59.0	10.4	29.2	94.7	47.5	52.3	58.2	65.4	72.9
2002	228	59.5	9.8	37.3	96.8	47.4	53.1	59.3	64.2	72.9
2003	242	59.9	9.7	38.9	87.5	47,7	53.6	58.7	66.1	73.7
2004	212	59.3	10.6	31.7	87.8	47.0	51.9	58.5	65.2	74.6
2005	263	60.6	10.5	12.8	103	48.0	53.5	61.1	66.2	71.6
2006	236	60.0	10.9	17.6	101	47.6	52.5	59.0	66.4	72.7
2007	277	62.3	11.0	30.1	91.6	48.7	53.0	62.4	69.5	76.6
2008	301	63.0	10.5	28.3	97.0	49.3	56.9	62.1	69.0	76.3
2009	285	62.5	10.7	40.8	95.5	49.6	54.8	61.7	69.6	75.7
2010	279	61.2	10.8	21.3	92.3	47.4	54.1	61.2	69.0	73.6
2011	271	63.4	11.0	24.5	92.0	49.8	54.8	63.2	70.8	75.7
2012	258	63.6	10.6	39.9	98.2	49.4	55.8	63.1	70.6	77.2
2013	122	63.4	10.3	33.2	91.4	52.0	56.6	62.8	69.1	75.7
1998-2013	3564	61.1	10.7	0.9	103	48.2	53.6	60.6	67.8	75.1

Table 3a

Age distribution parameters by year of diagnosis (MALES)

(incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	125	56.8	10.3	0.9	87.6	46.2	51.1	57.2	62.3	68.6
1999	134	58.6	10.0	37.1	87.0	48.6	51.2	57.0	64.2	73.6
2000	110	59.7	9.8	40.6	89.6	49.5	52.5	58.0	65.8	73.8
2001	121	58.3	9.5	29.2	81.2	47.5	52.0	58.2	65.4	69.9
2002	196	59.2	9.4	38.0	96.8	47.4	53.0	59.0	63.9	70.6
2003	195	59.4	9.0	39.6	87.5	48.1	53.4	58.5	65.9	72.6
2004	180	58.4	10.1	31.7	85.5	45.9	51.3	57.3	64.1	72.5
2005	211	60.1	10.2	12.8	99.0	47.7	53.5	61.0	65.7	70.4
2006	179	60.1	10.3	17.6	86.7	47.6	52.5	59.0	66.4	73.4
2007	224	62.1	10.4	39.1	91.6	49.0	52.9	62.5	69.5	75.6
2008	231	61.8	9.9	28.3	87.0	49.3	55.0	61.1	68.3	74.3
2009	226	62.2	10.1	40.8	90.7	49.6	54.8	61.8	69.4	73.9
2010	225	61.2	10.6	21.3	92.3	47.3	54.3	60.9	69.2	73.6
2011	211	63.3	10.5	32.1	89.2	49.7	54.1	63.2	71.0	75.5
2012	199	62.9	10.0	39.9	91.7	49.3	55.2	62.4	70.3	76.5
2013	90	63.3	9.3	33.2	84.4	53.4	57.8	62.8	68.9	74.9
1998-2013	2857	60.7	10.2	0.9	99.0	48.2	53.4	60.3	67.2	73.9

Table 3b

Age distribution parameters by year of diagnosis (FEMALES) (incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	20	63.0	12,1	50.7	86.7	51.3	53.8	58.3	72.3	84.0
1999	28	62.7	14.5	32.7	91.7	41.9	52.6	61.1	74.0	82.4
2000	28	56.7	12.6	31.0	81.3	39.8	49.5	57.7	61.0	77.0
2001	24	62.4	13.9	41.3	94.7	49.3	53.7	58.4	73.7	84.8
2002	32	61.9	12.1	37.3	83.6	47.6	53.7	60.8	70.8	78.9
2003	47	61.7	11.9	38.9	84.2	44.7	53.9	59.0	71.7	80.7
2004	32	64.8	12.1	36.3	87.8	50.9	56.2	64.8	75.7	80.5
2005	52	62.6	11.5	44.9	103	49.9	53.4	61.6	66.8	77.5
2006	57	59.9	12.8	34.7	101	46.3	51.6	58.8	65.6	72.5
2007	53	62.8	13.2	30.1	89.4	47.8	53.6	61.9	68.6	83.5
2008	70	66.9	11.4	35.5	97.0	55.1	61.1	66.4	70.8	83.3
2009	59	63.4	12.7	41.0	95.5	49.3	54.7	60.8	71.1	83.1
2010	54	61.4	11.6	33.3	90.0	48.8	53.4	62.9	68.3	71.8
2011	60	63.5	12.7	24.5	92.0	50.7	55.0	63.1	70.4	81.0
2012	59 /	66.2	12.2	44.0	98.2	51.7	57.8	64.7	73.2	82.9
2013	32	63.6	12.8	44.7	91.4	49.2	53.0	62.8	70.7	78.5
1998-2013	707	63.0	12.5	24.5	103	48.7	54.2	61.7	70.3	80.8

Table 4

Age distribution by 5-year age group and gender for period 1998-2013 (incl. DCO)

Age at									
diagnosis	Cases			Males			Females		
Years	n	%	Cum.%	n	%	Cum.%	n	%	Cum.%
0-4	1	0.0	0.0	/ 1	0.0	0.0			0.0
5-9	0	0.0	0.0			0.0			0.0
10-14	1	0.0	0.1	1	0.0	0.1			0.0
15-19	1	0.0	0.1	1	0.0	0.1			0.0
20-24	3	0.1	0.2	2	0.1	0.2	1	0.1	0.1
25-29	4	0.1	0.3	4	0.1	0.3			0.1
30-34	13	0.4	0.6	7	0.2	0.6	6	0.8	1.0
35-39	28	0.8	1.4	18	0.6	1.2	10	1.4	2.4
40 - 44	109	3.1	4.5	86	3.0	4.2	23	3.3	5.7
45-49	337	9.5	13.9	284	9.9	14.1	53	7.5	13.2
50-54	568	15.9	29.9	471	16.5	30.6	97	13.7	26.9
55-59	628	17.6	47.5	509	17.8	48.4	119	16.8	43.7
60-64	672	18.9	66.4	554	19.4	67.8	118	16.7	60.4
65-69	509	14.3	80.6	409	14.3	82.1	100	14.1	74.5
70-74	330	9.3	89.9	273	9.6	91.7	57	8.1	82.6
75-79	182	5.1	95.0	135	4.7	96.4	47	6.6	89.3
80-84	105	2.9	98.0	67	2.3	98.8	38	5.4	94.6
85+	73	2.0	100.0	35	1.2	100.0	38	5.4	100.0
All ages	3564	100.0		2857	100.0		707	100.0	

Included in the statistics are 35.0% multiple primaries in males and 36.5% in females.

Table 5

Age-specific incidence, DCO rate and proportion of all cancers for period 1998-2013

							Males	Females
			Males	Females	Males	Females	Prop.all	Prop.all
Age at			Age-	Age-	DCO rate	DCO rate	cancers	cancers
diagnosis	Males	Females	spec.	spec.	n=124	n=53	n=158258	n=153136
Years	n	n	incid.	incid.	%	%	%	%
0- 4	1		0.1	0.0	100.0		0.3	
5- 9			0.0	0.0				
10-14	1		0.1	0.0			0.6	
15-19	1		0.1	0.0			0.3	
20-24	2	1	0.1	0.1			0.3	0.2
25-29	4		0.2	0.0			0.4	
30-34	7	6	0.3	0.3		16.7	0.5	0.3
35-39	18	10	0.7	0.4		10.0	0.8	0.3
40-44	84	23	3.2	0.9	1.2	4.3	2.6	0.4
45-49	279	52	11.8	2.3	2.5	5.8	5.2	0.6
50-54	468	92	23.2	4.5	3.0	3.3	5.4	0.8
55-59	504	119	27.5	6.2	2.0	2.5	3.5	0.9
60-64	551	/ 117 /	31.1	6.2	3.6	4.3	2.5	0.7
65-69	405	97	25.7	5.6	4.7	3.1	1.5	0.5
70-74	270	57	21.1	3.8	8.1	7.0	1.0	0.3
75-79	134	47	16.2	4.0	5.2	10.6	0.6	0.3
80-84	67	37	13.4	4.0	13.4	24.3	0.5	0.2
85+	35	38	10.3	4.3	40.0	39.5	0.4	0.2
All ages	2831	696			4.4	7.6	1.8	0.5
Incidence								
Raw			9.5	2.2				
WS			6.0	1.3				
ES			8.2	1.8				
BRD-S			9.1	2.0				

The age-specific incidence characterizes the disease risk in a particular age group. The age distribution depends on the patient population frequency in each age group and reflects the tangible clinical picture of everyday patients care (see following chart).

Table 6a

Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of second primaries for period 1998-2013

MALES

	Observed E	xpected		LCL	UCL		DCO
Diagnosis	/ n /	n	SIR	95%	95%	EAR	%
	/ /						/
C03-C06 Oral cavity	31	0.9	32.8	-		‡ 49.2	9.7
C09-C10 Oropharynx	26	1.2	21.3	13.9	31.2 ‡	40.6	
C12-C13 Hypopharynx	/ 8	0.7	11.7	5.0	23.0	‡ 12.0	12.5
C15 Oesophagus	43	1.6	27.0	19.5	36.3 ‡	‡ 67.8	18.6
C16 Stomach	7	2.7	2.6	1.0	5.3 ‡	† 7.0	14.3
C18 Colon	14	6.6	2.1	1.2	3.6 ‡	‡ 12.1	
C19-C20 Rectum	5	4.5	1.1	0.4	2.6	0.9	
C21 Anus/canal	2	0.2	11.1	1.3	40.2 ‡	<sup>‡</sup> 3.0	
C22 Liver	9	2.1	4.3	2.0	8.2	‡ 11.3	11.1
C25 Pancreas	9	2.5	3.6	1.6	6.8	10.6	22.2
C30-C31 Sinuses	2	0.1	14.5	1.8	52.2 ‡	‡ 3.0	
C32 Larynx	27	1.0	27.2	17.9	39.6	42.6	25.9
C33-C34 Lung	83	9.2	9.1	~7.2	11.2 ‡	120.9	9.6
C43 Malign. melanoma	a 4	3.3	1.2/	0.3	3.1	1.1	
C61 Prostate	23	22.0	1.0	0.7	1.6	1.6	4.3
C64 Kidney	8	2.9	2.8	1.2	5.5 ‡	8.4	25.0
C65 Renal pelvis	2	0.3	7.5	0.9	27.3	2.8	
C67 Bladder	7	2.7	2.6	1.0	5.3	<sup>‡</sup> 7.0	14.3
C73 Thyroid	4	0.7	5.8	1.6	14.9	<sup>‡</sup> 5.4	25.0
C76-C79 CUP	4	1.2	3.3	0.9	8.6	4.6	
C82-C85 NHL	2	2.9	0.7	0.1	2.5	-1.4	
Other primaries	7	4.1	1.7	0.7	3.5	4.8	28.6
Not observed	0	2.8	0.0	0.0	1.3	-4.6	
All mult. primaries	327	76.1	4.3	3.8	4.8 ‡	‡ <b>410.8</b>	11.6
<u> -</u>							

Patients	1987
Median age at second malignancy (years)	63.2
Person-years	6108
Mean observation time (years)	3.1
Median observation time (years)	1.7

# The occurrence of second malignancy is statistically significant.

Observed second primaries with count 1 are pooled in category "Other primaries".

base\_C0914E.pdf

Table 6b

Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of second primaries

for period 1998-2013 FEMALES

	Observed	Expected		LCL	UCL		DCO
Diagnosis	n /	n	SIR	95%	95%	EAR	%
C03-C06 Oral cavity	5/	0.1	43.9	14.3	102.4 #	28.1	
C09-C10 Oropharynx	7	0.1	77.1	31.0	158.9 #	39.8	
C12-C13 Hypopharynx	4	0.0	158.7	43.2	406.3 #	22.9	
C15 Oesophagus	10	0.1	95.4	45.7	175.4 #	56.9	
C16 Stomach	2	0.5	4./1	0.5	15.0	8.7	
C18 Colon	6	1.4	4.3	1.6	9.5 #	26.6	
C22 Liver	3	0.2	18.1	3.7	52.9 #	16.3	33.3
C32 Larynx	3	0.0	81.5	16.8	238.2 #	17.1	
C33-C34 Lung	12	1.3	9.6	4.9	16.7 #	61.8	8.3
C50 Breast	6	5.6	1.1	0.4	2.3	2.0	
C53 Cervix uteri	3	0.3	11.5	2.4	33.7 #	15.8	
C56 Ovary	2	0.7	2.9	0.4	10.6	7.6	50.0
C64 Kidney	2	0.4	5.3	0.6	19.1	9.3	
C70-C72 CNS cancer	2	0.2	8.8	1.1	31.8 #	10.2	50.0
Other primaries	10	3.4	2.9	1.4	5.4 #	38.0	20.0
Not observed	0	2.3	0.0	0.0	1.6	-13.5	
All mult. primaries	77	16.6	4.6	3.7	5.8 #	347.6	7.8

Patients	474
Median age at second malignancy (years)	63.8
Person-years	1738
Mean observation time (years)	3.7
Median observation time (years)	2.4

# The occurrence of second malignancy is statistically significant.

Observed second primaries with count 1 are pooled in category "Other primaries".








Figure 7. Age distribution and age-specific incidence







**Figure 7a.** Age-specific incidence in MCR registry areas compared to SEER (Surveillance, Epidemiology, and End Results, USA).



Reference:

Surveillance, Epidemiology, and End Results (SEER) Program SEER\*Stat Database: Incidence - SEER 18 Regs Research Data, released April 2014, based on the November 2013 submission. http://www.seer.cancer.gov.





Figure 8. Cumulative follow-up years depending on time since diagnosis


The increase of the lost to follow-up rate can be interpreted as a consequence of a declining number of survivors over time.



#### Average incidence (world standard population) 2007 - 2013: Males



#### Average incidence (world standard population) 2007 - 2013: Females




**Figure 9a.** Map of cancer incidence (world standard population, incl. DCO cases) by county averaged for period 2007 to 2013. According to their individual incidence rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 5.3/100,000 WS N=1,389, females 1.3/100,000 WS N=378).


The results should be interpreted with caution! E.g., in county Ebersberg with a population of 64,928 female residents (averaged) in the period from 2007 to 2013 a total of 14 women were identified with newly diagnosed pharynx cancer. Therefore, the mean incidence rate for this cancer type in this area can be calculated at 1.8/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.7 and 3.6/100,000.

base C0914E.pdf

#### Standardized incidence ratio (SIR) 2007 - 2013: Males



### Standardized incidence ratio (SIR) 2007 - 2013: Females



**Figure 9b.** Map of standardized incidence ratio (SIR, incl. DCO cases) by county averaged for period 2007 to 2013. According to their individual SIR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=1,389, females N=378).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 64,642 female residents (averaged) in the period from 2007 to 2013 a total of 14 women were identified with newly diagnosed pharynx cancer. Therefore, the mean standardized incidence ratio (SIR) for this cancer type in this area can be calculated at 1.36. Though, the value of this parameter may vary with an underlying probability of 99% between 0.60 and 2.60, and is therefore not statistically striking.

#### **MORTALITY**

#### Table 10a

Patient cohorts of incident cancers by year of diagnosis, follow-up status, proportion of DCO, deaths among the annual cohorts, and proportion of available death certificates (with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.64 m as of 2007, respectively)

	Incident	Prop. actively	Prop.		Prop.	Prop. deaths with death
Year of	cases	followed	DCO	Deaths	deaths	certific.
diagnosis	n	%	%	n	%	%
1998	145	100.0	4.8	122	84.1	95.9
1999	162	98.8	4.9	131	80.9	90.8
2000	138	97.1	3.6	114	82.6	94.7
2001	145	95.9	5.5	110	75.9	96.4
2002	228	98.2	8.8	176	77.2	96.0
2003	242	98.3	2.1	191	78.9	96.9
2004	212	98.6	3.8	161	75.9	96.3
2005	263	97.0	5.3	177	67.3	98.3
2006	236	97.5	2.1	158	66.9	98.7
2007	277	92.1	9.0	179	64.6	96.1
2008	301	82.4	4.0	200	66.4	97.5
2009	285	82.1	2.8	182	63.9	96.7
2010	279	76.7	4.7	146	52.3	99.3
2011	271	80.1	5.2	133	49.1	94.7
2012	258	80.6	7.0	109	42.2	97.2
2013	122	100.0	7.4	48	39.3	85.4
1998-2013	3564	90.7	5.0	2337	65.6	96.3

Table 10b

Annual cohorts of incident cancers and deaths, proportion of death certificates and cases deceased the same year of cancer diagnosis (incl. DCO)

(with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.64 m as of 2007, respectively)

			Prop. deaths		Prop.
Year of	Incident		with death	Deaths in	deaths in
diagnosis/	cases	Deaths	certific.	same year	same year
death	n /	n	%	n	%
1998	145	116	90.5	27	18.6
1999	162	127	87.4	34	21.0
2000	138	113	95.6	21	15.2
2001	145	112	92.9	27	18.6
2002	228	168	97.6	46	20.2
2003	242	172	96.5	41	16.9
2004	212	178	96.6	31	14.6
2005	263	167	95.8	47	17.9
2006	236	186	98.4	38	16.1
2007	277	230	97.8	58	20.9
2008	301	206	98.5	52	17.3
2009	285	195	99.0	46	16.1
2010	279	207	99.0	44	15.8
2011	271	206	98.1	59	21.8
2012	258	227	97.8	54	20.9
2013	122	203	98.0	32	26.2
1998-2013	3564	2813	96.8	657	18.4

Table 10c

Annual cohorts of deaths, proportion of cancer-related and non-cancerrelated deaths, and cancer recorded on death certificates (incl. DCO)

(with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.64 m as of 2007, respectively)

				Prop.
				cancer
		Prop.	Prop.	recorded
		cancer-	non-cancer-	on death
Year of	Deaths	related	related	certificate
death	n	%	8	%
1998	116	77.6	22.4	94.3
1999	127	68.5	31.5	91.0
2000	113	85.0	15.0	93.5
2001	112	77.7	22.3	92.3
2002	168	81.5	18.5	91.5
2003	172	81.4	18.6	92.8
2004	178	82.6	17.4	91.3
2005	167	85.6	14.4	93.8
2006	186	84.9	15.1	91.3
2007	230	83.5	16.5	92.4
2008	206	82.0	18.0	89.2
2009	195	82.6	17.4	96.9
2010	207	83.6	16.4	92.7
2011	206	75.7	24.3	86.6
2012	227	82.4	17.6	91.9
2013	203	77.3	22.7	89.4
1998-2013	2813	81.1	18.9	91.8

Table 11a  $\begin{tabular}{ll} Medians of age at death according to the grouping in Table 10 \\ \hline MALES \end{tabular}$ 

Year of death	Deaths n	Age at death (all causes)	Age at death (cancer-related)	Age at death (non-cancer-related) Years	Age at death (according to death certificate) Years
1998	90	59.2	57.4	64.4	59.3
1999	101	60.5	58.8	62.9	59.0
2000	91	60.4	59.1	65.5	59.7
2001	92	60.1	59.0	65.5	60.3
2002	143	60.2	59.7	63.9	59.8
2003	148	62.5	61.8	67.6	61.8
2004	149	60.7	60.1	63.5	60.2
2005	141	62.1	62.0	64.0	62.4
2006	158	63.8	62.7	66.5	62.9
2007	191	63.4	62.0	69.7	63.0
2008	161	66.9	66.7	68.2	67.0
2009	155	64.5	64.4	67.0	64.5
2010	173	63.9	63.0	72.0	63.7
2011	172	66.1	63.8	70.9	65.4
2012	176	67.7	67.7	67.1	67.5
2013	158	66.4	64.5	69.4	64.9
1998-2013	2299	63.2	62.3	67.4	62.9

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 11b  $\label{eq:medians} \mbox{Medians of age at death according to the grouping in Table 10 }$ 

Year of death	Deaths n	Age at death (all causes)	Age at death (cancer-related) Years	Age at death (non-cancer-related) Years	Age at death (according to death certificate)
1998	26	71.5	69.6	77.9	71.5
1999	26	62.6	62.9	58.1	60.8
2000	22	55.9	55.6	74.0	55.9
2001	20	64.3	63.4	66.2	63.4
2002	25	66.2	64.9	73.8	66.8
2003	24	62.2	62.2	68.2	63.4
2004	29	73.8	73.8	72.0	74.2
2005	26	64.0	60.3	72.4	63.6
2006	28	67.3	66.9	75.1	67.3
2007	39	67.6	66.9	74.0	67.0
2008	45	66.9	66.9	64.7	66.9
2009	40	68.9	68.5	74.4	68.9
2010	34	64.1	62.7	71.1	63.7
2011	34	66.1	64.9	76.1	64.9
2012	51	71.5	71.5	77.0	70.6
2013	45	69.0	68.3	76.5	68.4
1998-2013	514	67.4	66.5	73.1	66.9

By 2010, life expectancy for a newborn male in Germany is 77.5 years compared with 82.6 years for his female counterpart.

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 12a Mortality measures (cancer-related death) and mortality-incidence-index by year of death MALES

Year of	Deaths	Mort.	MI-Index	Mort.	MI-Index	Mort.	MI-Index	Mort.	MI-Index
death	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
1998	70	6.3	0.56	4.4	0.57	5.8	0.57	6.3	0.58
1999	74	6.6	0.55	4.2	0.53	5.9	0.54	6.7	0.56
2000	78	6.8	0.71	4.4	0.68	6.2	0.69	7.1	0.72
2001	72	6.2	0.60	4.1	0.58	5.7	0.60	6.2	0.61
2002	120	6.4	0.62	4.2	0.61	5.8	0.61	6.4	0.63
2003	122	6.5	0.63	4.1	0.59	5.7	0.60	6.3	0.63
2004	124	6.6	0.70	4.2	0.68	5.8	0.70	6.3	0.70
2005	122	6.4	0.58	3.9	0.55	5.5	0.57	6.1	0.58
2006	135	7.0	0.75	4.3	0.72	6.0	0.73	6.8	0.75
2007	159	7.2	0.72	4.3	0.72	6.1	0.73	6.9	0.73
2008	133	6.0	0.58	3.4	0.53	4.8	0.55	5.6	0.57
2009	131	5.9	0.58	3.4	0.56	4.8	0.57	5.6	0.59
2010	148	6.6	0.66	3.8	0.64	5.4	0.66	6.2	0.68
2011	132	5.8	0.64	3.3	0.64	4.6	0.64	5.3	0.65
2012	140	6.1	0.71	3.2	0.63	4.8	0.67	5.8	0.72
2013	124	5.4	1.41	3.0	1.27	4.3	1.33	5.0	1.36
1998-2013	1884	6.3	0.67	3.8	0.64	5.4	0.65	6.1	0.67

Table 12b

Mortality measures (cancer-related death) and mortality-incidence-index by year of death FEMALES

Year of	Deaths	Mort.	MI-Index		MI-Index		MI-Index		
death	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
1998	20	1.7	1.00	0.8	0.86	1.2	0.88	1.5	1.00
1999	13	1.1	0.46	0.6	0.42	0.8	0.43	1.0	0.46
2000	19	1.6	0.68	1.0	0.67	1.3	0.68	1.5	0.69
2001	15	1.2	0.63	0.6	0.54	0.9	0.53	1.0	0.55
2002	17	0.9	0.53	0.5	0.50	0.7	0.52	0.8	0.51
2003	18	0.9	0.38	0.5	0.37	0.7	0.38	0.8	0.37
2004	23	1.2	0.72	0.5	0.64	0.8	0.63	1.0	0.70
2005	21	1.1	0.41	0.6	0.42	0.9	0.43	1.0	0.41
2006	23	1.1	0.41	0.6	0.31	0.8	0.33	1.0	0.37
2007	33	1.4	0.66	0.7	0.58	1.0	0.60	1.2	0.64
2008	36	1.6	0.52	0.8	0.54	1.2	0.55	1.3	0.52
2009	31	1.3	0.53	0.7	0.47	0.9	0.47	1.1	0.50
2010	25	1.1	0.48	0.6	0.46	0.9	0.47	1.0	0.50
2011	24	1.0	0.41	0.5	0.37	0.8	0.38	0.8	0.39
2012	47	2.0	0.80	0.9	0.66	1.3	0.69	1.5	0.72
2013	33	1.4	1.06	0.7	0.94	1.0	0.96	1.2	1.05
1998-2013	398	1.3	0.57	0.7	0.51	0.9	0.53	1.1	0.55

Table 13

Age distribution of age at death (cancer-related) for period 1998-2013

(incl. multiple primaries)

Age at								
death	Cases		Males			Females		
Years	n	% Cur	n.% n	%	Cum.%	n	%	Cum.%
0-4	1	0.0	0.0 / 1	0.1	0.1			0.0
5-9	0	0.0	0.0		0.1			0.0
10-14	0	0.0	0.0		0.1			0.0
15-19	0	0.0	0.0		0.1			0.0
20-24	0	0.0	0.0		0.1/			0.0
25-29	0	0.0	0.0		0.1			0.0
30-34	2	0.1	0.1 1	0.1	0,1	1	0.2	0.2
35-39	11	0.5	0.6 8	0.4	0.5	3	0.7	1.0
40 - 44	40	1.7	2.3 36	1.9	2.4	4	1.0	2.0
45-49	147	6.3	3.6 127	6.6	9.0	20	4.9	6.9
50-54	283	12.1 20	253	13.1	22.1	30	7.4	14.3
55-59	442	18.9 39	9.7 378	19.6	41.7	64	15.8	30.1
60-64	440	18.8 58	3.5 371	19.2	60.9	69	17.0	47.2
65-69	360	15.4 73	3.9 289	15.0	75.9	71	17.5	64.7
70-74	265	11.3 89	5.3 221	11.5	87.3	44	10.9	75.6
75-79	177	7.6 92	2.8 140	7.3	94.6	37	9.1	84.7
80-84	97	4.2 9	7.0 70	3.6	98.2	27	6.7	91.4
85+	70	3.0 100	0.0 35	1.8	100.0	35	8.6	100.0
All ages	2335	100.0	1930	100.0		405	100.0	

Included in the statistics are 35.0% multiple primaries in males and 36.5% in females.

Table 14 Age-specific mortality (cancer-related) and proportion of all cancers for period 1998-2013 (incl. multiple primaries)

			Males		Females		Males	Females
Age at			Age-		Age-		Prop.all	Prop.all
death	Males	Females	spec.		spec.		cancers	cancers
Years	n	n	mortal.	MI-index	mortal.	MI-index	%	%
0 - 4	1		0.1	1.00	0.0		3.0	
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24			0.0		0.0			
25-29			0.0		0.0			
30-34	1	1	0.0	0.14	0.0		0.5	0.4
35-39	8	3	0.3	0.44	0.1	0.30	2.0	0.6
40-44	36	4	1.4		0.2		4.2	0.4
45-49	127	20	5.4		0.9	0.38	7.0	1.0
50-54	253	30	12.5		1.5		7.7	1.0
55-59	378	64	20.6	0.74	3.3	0.54	6.4	1.3
60-64	371	69	20.9		3.7		4.2	1.1
65-69	289	71	18.3	0.71	4.1	0.71	2.4	0.9
70-74	221	44	17.3		2.9	0.77	1.6	0.4
75-79	140	37	16.9		3.1		1.1	0.3
80-84	70	27	14.0	1.04	2.9		0.6	0.2
85+	35	35	10.3	1.00	3.9	0.92	0.4	0.3
		\						
All ages	1930	405					2.4	0.6
Mortality				0.50				
Raw			6.5	0.68	1.3			
WS			3.9		0.7			
ES			5.5	0.66	1.0	0.53		
BRD-S			6.3	0.68	1.1	0.55		
D34 1 70								
PYLL-70			62.0		10.0			
per 100,000			63.0		10.2			
ES			56.8		8.8			
AYLL-70			11.5		10.4			

The rates underestimate the prognosis if other synchronous cancers are prognostic unfavorable.

Table 15a

Multiple primaries in deaths in period 1998-2013

MALES

					Syn- chron	Syn- chron		
	Total	Total	Pre	Pre	±30d	±30d	Post	Post
Diagnosis	n	% ↓	n	<b>←</b> %	n	<b>←%</b>	n	←%
C03-C06 Oral cavity	103	11.9	44	42.7	12	11.7	47	45.6
C09-C10 Oropharynx	60	6.9			16	26.7	44	73.3
C12-C13 Hypopharynx	56	6.5			24	42.9	32	57.1
C15 Oesophagus	95	11.0	21	22.1	11	11.6	63	66.3
C16 Stomach	15	1.7	4	26.7	_ 2	13.3	9	60.0
C18 Colon	33	3.8	17	51.5	1	3.0	15	45.5
C19-C20 Rectum	12	1.4	5	41.7	1	8.3	6	50.0
C22 Liver	18	2.1			3	16.7	15	83.3
C25 Pancreas	20	2.3	2	10.0	1	5.0	17	85.0
C32 Larynx	33	3.8			5	15.2	28	84.8
C33-C34 Lung	163	18.9	27	16.6	22	13.5	114	69.9
C43 Malign. melanoma	12	1.4	6	50.0	2	16.7	4	33.3
C44 Skin others	56	6.5	17	30.4	7	12.5	32	57.1
C61 Prostate	48	5.6	24	50.0	3	6.3	21	43.8
C64 Kidney	15	1.7	7	46.7	2	13.3	6	40.0
C67 Bladder	26	3.0	14	53.8	1	3.8	11	42.3
C76-C79 CUP	23	2.7	14	60.9			9	39.1
Other primaries	76	8.8	28	36.8	9	11.8	39	51.3
All mult. primaries	864	100.0	230	26.6	122	14.1	512	59.3

Multiple primaries with number of cases 1 to 7 are pooled in category "Other primaries".

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a multiple malignancy.

Table 15b

Multiple primaries in deaths in period 1998-2013
FEMALES

					Syn- chron	Syn- chron		
	Total	Total	Pre	Pre	±30d	±30d	Post	Post
Diagnosis	n /	%↓	n	<b>←</b> %	n	<b>←%</b>	n	<b>←%</b>
C03-C06 Oral cavity	29	13.9	19	65.5	3	10.3	7	24.1
C09-C10 Oropharynx	/5	2.4			1	20.0	4	80.0
C12-C13 Hypopharynx	/ 7	3.4			4	57.1	3	42.9
C15 Oesophagus	/ 18	8.7	2	11/1	5	27.8	11	61.1
C16 Stomach	3	1.4			/ 1	33.3	2	66.7
C18 Colon	9	4.3	5	55.6	/ 1	11.1	3	33.3
C21 Anus/canal	3	1.4	2	66.7			1	33.3
C30-C31 Sinuses	4	1.9	2	50.0			2	50.0
C32 Larynx	12	5.8	4	33.3	1	8.3	7	58.3
C33-C34 Lung	25	12.0	2	8.0	3	12.0	20	80.0
C44 Skin others	4	1.9					4	100.0
C50 Breast	36	17.3	28	77.8	3	8.3	5 /	13.9
C53 Cervix uteri	6	2.9	5	83.3			1	16.7
C54 Corpus uteri	4	1.9	3	75.0			1	25.0
C56 Ovary	3	1.4	2	66.7			1	33.3
C67 Bladder	4	1.9	3	75.0			1	25.0
C73 Thyroid	4	1.9	3	75.0	1	25.0		
C76-C79 CUP	9	4.3	5	55.6			4	44.4
C82-C85 NHL	3	1.4	2	66.7			1	33.3
C91-C96 Leukaemia	3	1.4	1	33.3			2	66.7
Other primaries	17	8.2	5	29.4	4	23.5	8	47.1
-								
All mult. primaries	208	100.0	93	44.7	27	13.0	88	42.3
/-								

Multiple primaries with number of cases 1 to 2 are pooled in category "Other primaries".

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a multiple malignancy.

Table 16

Age-specific mortality (cancer-related) and proportion of all cancers for period 1998-2013

(Singular primaries only \*)


			Males		Females		Males	Females
Age at			Age-		Age-		Prop.all	Prop.all
death	Males	Females	spec.		spec.		cancers	cancers
Years	n	n	mortal.	MI-index	mortal.	MI-index	%	%
0 - 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24			0.0		0.0			
25-29			0.0		0.0			
30-34	1	1	0.0	0.14	0.0	0.17	0.6	0.5
35-39	7	1	0.3	0.44	0.0	0.13	1.9	0.2
40-44	31	3	1.2	0.41	0.1	0.14	3.9	0.3
45-49	107	17	4.5	0.44	0.7	0.40	6.5	1.0
50-54	216	23	10.7	0.52	1.1	0.30	7.5	0.9
55-59	317	53	17.3	0.75	2.8	0.60	6.2	1.3
60-64	295	47	16.6	0.66	2.5	0.48	4.0	0.9
65-69	219	55	13.9	0.69	3.2	0.72	2.3	0.8
70-74	176	31	13.7	0.89	2.0	0.76	1.6	0.4
75-79	100	25	12.1		2.1		1.0	0.3
80-84	44	17	8.8		1.8		0.5	0.2
85+	28	22	8.2		2.5	0.81	0.4	0.2
All ages	1541	295					2.4	0.5
Mortality								
Raw			5.2	0.67	0.9	0.54		
WS			3.2		0.5			
ES			4.4		0.7			
BRD-S			5.0	0.67	0.8	0.53		
PYLL-70								
per 100,000			52.4		7.9			
ES			47.2		6.8			
AYLL-70			11.8		10.5			

<sup>\*</sup> See corresponding tables with multiple primaries.

Table 17 Age-specific mortality (cancer-related) and proportion of all cancers for period 1998-2013 (Single primaries only \*)

			Males		Females		Males	Females
Age at			Age-		Age-		Prop.all	Prop.all
death	Males	Females	spec.		spec.		cancers	cancers
Years	n	n	mortal.	MI-index	mortal.	MI-index	%	%
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24			0.0		0.0			
25-29			0.0		0.0			
30-34	1	1	0.0	0.17	0.0	0.17	0.6	0.5
35-39	7	1	0.3	0.47	0.0	0.13	2.0	0.2
40-44	29	3	1.1	0.43	0.1		3.9	0.3
45-49	94	11	4.0	0.43	0.5	0.29	6.1	0.7
50-54	177	20	8.8	0.48	1.0	0.29	6.8	0.9
55-59	262	43	14.3	0.69	2.2	0.60	5.7	1.2
60-64	239	38	13.5	0.60	2.0	0.44	3.6	0.8
65-69	171	47	10.8	0.63	2.7	0.67	2.0	0.8
70-74	123	24	9.6	0.72	1.6	0.65	1.4	0.4
75-79	64	15	7.7	0.74	1.3	0.56	0.8	0.2
80-84	30	14	6.0	0.77	1.5	0.54	0.5	0.2
85+	23	18	6.7	0.96	2.0	0.69	0.4	0.2
All ages	1220	235					2.3	0.5
Mortality								
Raw			4.1	0.59	0.8	0.48		
WS			2.5	0.57	0.4	0.44		
ES			3.5	0.59	0.6	0.46		
BRD-S			3.9	0.60	0.6	0.47		
PYLL-70								
per 100,000			43.9		6.4			
ES			39.5		5.5			
AYLL-70			12.0		10.3			
, 0			12.0		10.5			

<sup>\*</sup> See corresponding tables with multiple primaries.




**Figure 18.** Distribution of age at death (bars) and age-specific mortality (all patients: solid line, patients with single primaries: dotted line). The age-specific incidence is additionally plotted for comparison (dashed line).


The difference between age at diagnosis (Table 3) and age at pharynx cancer-related death (see Table 10) should be considered.



### Average mortality (world standard population) 2007 - 2013: Males




#### Average mortality (world standard population) 2007 - 2013: Females




**Figure 19a.** Map of cancer mortality (world standard population) by county averaged for period 2007 to 2013. According to their individual mortality rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 3.5/100,000 WS N=957, females 0.7/100,000 WS N=227).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 64,928 female residents (averaged) in the period from 2007 to 2013 a total of 6 women died from pharynx cancer. Therefore, the mean mortality rate for this cancer type in this area can be calculated at 0.6/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.1 and 1.9/100,000.

#### Standardized mortality ratio (SMR) 2007 - 2013: Males



### Standardized mortality ratio (SMR) 2007 - 2013: Females



**Figure 19b.** Map of standardized mortality ratio (SMR, incl. DCO cases) by county averaged for period 2007 to 2013. According to their individual SMR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=957, females N=227).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 64,642 female residents (averaged) in the period from 2007 to 2013 a total of 6 women died from pharynx cancer. Therefore, the mean standardized mortality ratio (SMR) for this cancer type in this area can be calculated at 0.98. Though, the value of this parameter may vary with an underlying probability of 99% between 0.25 and 2.56, and is therefore not statistically striking.

#### Statistical Notes

In all tables and figures the respective reference values should be carefully considered. The incidence rates include diagnoses (with multiple primary), and death certificate only (DCO) cases. For mortality statistics patients, diagnoses and progressive course of disease are presented. In the calculations, all courses of disease are considered whereby progressions occurred and/or death certificate identified progressive cancers were ascertained. Additionally there are three groups of disease course to consider:

### 1. All multiple primaries included

The mortality statistic describes the tumor-specific death, independent of any malignancy. The patient perspective, induced secondary malignancies, and the problem of multiple malignancies from the same primary tumor all have reasons for their inclusion.

#### 2. First singular primary (no information about other prior or synchronous malignancy)

The mortality statistic describes the cancer-related death for patients who have no therapeutic restrictions due to a previous or synchronous cancer. These statistics are comparable to studies that have exclusion criteria based on a second malignancy.

### **3. Single primary** (no information about other prior, syn- or metachronous malignancy)

The mortality statistic describes the tumor-specific death that occurs without any impact through secondary primaries, earlier, synchronous, later or induced. Precisely the difference between disease group 1 and 2 highlight the magnitude of the problem of secondary malignancies.

For this reason differences appear concerning official mono-causal mortality statistics. To judge the maximum deviation, 2 further tables are presented. In the first table the distribution of secondary malignancies before, at or after the described cancer are shown, that could be an alternative cause of death. In the second table, the age-specific mortality rates for all courses of disease, without designation of secondary malignancies are shown.

A previously minimally acknowledged statistic is the **age at death**, which allows for a good assessment of the quality of classification of the apparent tumor-specific death. For assumed tumor-independent deaths, the age of death should be estimated from the age of diagnosis and the normal life expectancy, whereas tumor-dependent deaths can be estimated from the age of diagnosis plus the average tumor-specific life expectancy. The comparison of different tumors demonstrates this association, if the causes of cancer and the competing cause of death are independent of each other (e.g. breast and colon versus head/neck and lung).

The index from mortality and incidence (Mortality-Incidence ratio, **MI-index**) is a statistic that allows for the evaluation of the quality of data. For diseases with poor prognoses, comparable values are obtained from all age groups, because to a large extent, the numerator and denominator contain the same cases. For tumors with a good prognosis, increasing and decreasing incidence and age-specific differences in prognosis can more strongly alter the MI- index. Additionally, attention should be paid to the confidence intervals where fewer cases are reported.

The complexity of problems identified here emphasizes the importance of relative survival data for the appropriate analysis of long term results.

As a measurement of the burden of disease, the number of potential life years loss due to premature deaths in a cohort can be calculated (**PYLL**, potential years of life lost, standardized per 100,000 persons or per European standard) as well as the average loss of life years per individual (**AYLL**, average years of life lost). Depending upon the analytic aim (health economy, prevention, health care research) different methods exist for the generation of these measurements. In the results presented here, the age for a premature death is considered to be before 70 years, according to the guidelines of the OECD and the WHO (as seen in the abbreviation PYLL-70 or AYLL-70).

#### **Shortcuts**

FRG Federal Republic of Germany

GEKID Association of Population-based Cancer Registries in Germany

(Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.)

MCR Munich Cancer Registry (Tumorregister München)
SEER Surveillance, Epidemiology, and End Results (USA)

AYLL-70 Average years of life lost prior to age 70 given a person dies before that age

BRD-S German standard population

DCO Death certificate only EAR Excess absolute risk

= excess cancer cases (O - E) per 10,000 person-years

ES European standard population (old)

LCL Lower confidence limit

MI-index Ratio between mortality and incidence

PYLL-70 Potential years of life lost prior to age 70 given a person dies before that age

SIR Standardized incidence ratio SMR Standardized mortality ratio UCL Upper confidence limit WS World standard population

#### **Recommended Citation**

Munich Cancer Registry. Baseline statistics C05.1, C05.2, C09-C14: Pharynx cancer [Internet]. 2015 [updated 2015 May 19; cited 2015 Jul 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/base/base C0914E.pdf

#### Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

#### Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

## Index of figures and tables

Fig./Tbl	l.	Page
1	Pts cohorts, DCO, mult. prim., follow-up / yr	4
1a	Gender distribution by year of diagnosis	5
2	Incidence by year of diagnosis	6
3	Age distribution parameters by year of diagnosis	7
4	Age distribution by 5-year age group and gender	9
5	Age-specific incidence and DCO rate	10
6	Standardized incidence ratio of second primaries	11
7	Age distribution and age-specific incidence (chart)	13
7a	Age-specific incidence internationally (chart)	14
8	Cumulative follow-up years (chart)	15
9a	Map of cancer incidence (WS) by county (chart)	16
9b	Standardized incidence ratio (SIR) by county (chart)	17
10a	Pts incident cohorts and mortality / yr	18
10b	Incidence and mortality by year of diagnosis	19
10c	Cancer-related deaths, death certification available / yr	20
11	Medians of age at death / yr	21
12	Mortality by year of death	23
13	Distribution of age at death	24
14	Age-specific mortality	25
15	Multiple primaries in deaths	26
16	Age-specific mortality (first primaries)	28
17	Age-specific mortality (single primaries)	29
18	Age distribution and age-specific mortality (chart)	30
19a	Map of cancer mortality (WS) by county (chart)	31
19b	Standardized mortality ratio (SMR) by county (chart)	32